Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients

Rabea Asleh, Alexandros Briasoulis, Naveen L. Pereira, Barry A. Boilson, Brooks S. Edwards, Rosalyn Adigun, Simon Maltais, Richard C. Daly, Amir Lerman and Sudhir S. Kushwaha*

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA

Abstract

Aims Early studies from the 1990s have shown that statins improve survival and attenuate cardiac allograft vasculopathy (CAV). However, little contemporary data are available on the incremental benefit of statins with the current use of new-generation immunosuppressive agents and the use of coronary intravascular ultrasound for assessment of CAV. We sought to investigate the effect of early statin (ES) as compared with late statin (LS) initiation after heart transplantation (HT) on long-term CAV progression and clinical outcomes in a large contemporary HT cohort.

Methods and results We analysed a cohort of 409 adult HT recipients. CAV progression was assessed by serial coronary intravascular ultrasound volumetric measurements of the differences between baseline and last follow-up plaque volume (PV) and plaque index (PV/vessel volume ratio). CAV progression and clinical outcomes were compared between the ES (<2 years after HT) and the LS (>2 years after HT) groups. During a median follow-up of 8.2 years, ES resulted in significantly lower change (Δ) of plaque index (+3.8% ± 1.7% vs. +8.2% ± 3.6%; P = 0.0008) and PV (+0.8 ± 0.3 vs. +1.9 ± 1.2; P = 0.045) compared with LS group. In a Cox proportional hazards regression model and after adjustment for baseline characteristics, ES was associated with a 52% decreased risk of CAV-associated events (hazard ratio 0.48, 95% confidence interval: 0.27–0.91; P = 0.025) and a 42% decreased risk of the composite endpoint of all-cause mortality and CAV-associated events (hazard ratio 0.58, 95% confidence interval: 0.38–0.91; P = 0.019).

Conclusions Early initiation of statin therapy after HT results in attenuated CAV progression as well as in decreased CAV-related events and mortality.

Keywords Cardiac allograft vasculopathy; Statins; Heart transplantation; Coronary intravascular ultrasound

Introduction

Although the survival after heart transplantation (HT) is steadily improving,1 cardiac allograft vasculopathy (CAV) remains the major cause of morbidity and mortality beyond the first year after HT.2 From a pathophysiological standpoint, an inflammatory fibroproliferative process, characterized by immune-mediated endothelial damage, perivascular inflammation and subendothelial accumulation of lymphocytes, progressive intimal smooth muscle cell proliferation, and fibrosis, leads to diffuse concentric lumen obliteration of epicardial as well as small distal coronary arteries.3 The incidence of CAV has decreased slightly over time, but the prevalence is estimated to be 30% and 50% at 5 and 10 years after HT, respectively.2,4 Because of atypical and often absent symptoms of CAV, annual routine screening with coronary angiography (CA) remains the standard diagnostic modality.5 Because of the
diffuse, concentric nature of CAV, CA may underestimate the severity of the disease. Therefore, the addition of intravascular ultrasound (IVUS) improves diagnostic accuracy and predictive value of CAV detection.6

Statins inhibit the rate-limiting enzyme of the mevalonate pathway of cholesterol synthesis, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, which results in lower plasma cholesterol levels. Beyond their lipid-lowering effects, statins exert anti-inflammatory properties, improve endothelial-dependent vasodilation, increase bioavailability of nitric oxide,7 and reduce free radical release in the vasculature via reduced expression of NADPH oxidase subunit p22phox.8 Previous randomized, controlled trials have demonstrated significant reduction of the incidence of CAV and improved long-term survival with early initiation of statins after HT.9–13 Pravastatin at a dose of 20 mg/day, initiated within 2 weeks after HT and up-titrated to 40 mg/day, attenuated CAV progression and improved survival with the benefits persisting at 10 years after HT.9,13 Similar findings have been observed with simvastatin.10,11 However, these early studies from the 1990s are limited by the use of first-generation immunosuppressive agents such as azathioprine and cyclosporine and the lack of robust analysis of CAV with IVUS, which is currently considered the gold standard technology for accurate assessment of CAV incidence and progression. In the present HT era of novel immunosuppression therapies, including the accumulating data on the beneficial role of mTOR inhibitors in attenuating CAV progression, the incremental benefit of early statin therapy among contemporary HT recipients is unclear.

We therefore sought to investigate the long-term effects of timing of statin initiation after HT on CAV progression, as assessed by serial IVUS studies, and on long-term clinical outcomes, including CAV-associated events and mortality, among a contemporary HT cohort of patients.

Methods

Data source

This was a non-randomized, retrospective, single-centre study approved by the Institutional Review Board of Mayo Clinic College of Medicine. We retrospectively analysed a long-term follow-up cohort of 409 patients who underwent HT at the Mayo Clinic, Rochester, Minnesota, during the period 1994 through January 2015.

Clinical and demographic data

Demographic, clinical follow-up, and laboratory data were obtained by review of the patients medical records and from the prospectively collected clinical database. Immunosuppressive medications were reviewed and recorded at each outpatient visit post-transplant. The estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration equation.

Immunosuppression

All HT recipients received induction therapy with low-dose OKT3 or anti-thymocyte globulin as part of a standard induction protocol and a three-drug maintenance immunosuppressive regimen consisting of a calcineurin inhibitor (CNI) (cyclosporine A or tacrolimus), an antimetabolite agent (mycophenolate mofetil or azathioprine), and tapering doses of prednisone post-transplant. Among 409 transplant recipients, 272 patients were converted to sirolimus (SRL) at a median time of 1.2 (interquartile range: 0.6–3.3) years post-transplant. The reasons for conversion to SRL varied according to the period of conversion. Until July 2006, 75 patients were converted to SRL due to impaired renal function secondary to CNI (eGFR ≤ 50 mL/min and lack of any other identifiable causes of renal dysfunction) in 45 patients, CAV International Society for Heart and Lung Transplantation (ISHLT) grade 2 or worse detected on annual CA in 10 patients, intolerance of CNI therapy due to significant side effects in 12 patients, and conversion as part of our newly introduced routine protocol in only 8 patients. Since July 2006, a routine conversion protocol from CNI to SRL was introduced in 202 patients. Stable patients at least 3 months post-transplant, without evidence of rejection, on low doses of prednisone, received gradually increasing doses of SRL to achieve plasma levels of 10–14 ng/mL, and once SRL target levels were achieved, CNI dose was gradually reduced until complete withdrawal of CNI therapy. The dose of secondary immunosuppression, mycophenolate mofetil or azathioprine, as well as the dose of prednisone remained unchanged during the conversion process. Twelve patients in the SRL group remained on a combination of SRL and a reduced dose of CNI due to repeated rejection. Twenty-six patients were converted back from SRL-based to CNI-based immunosuppression regimen due to a planned surgery or SRL-related side effects. Trough levels of SRL were measured through the use of high-performance liquid chromatography with tandem mass spectroscopy (API 4000, Applied Biosystems, Foster City, California) and adjusted according to the institutional protocols.

Statins

We studied two groups of patients according to the timing of statin treatment initiation. The early statin (ES) administration group started statin treatment within the first 2 years post-transplant at a median time of 29 days (range 14.6 to
65.7 days) after transplantation. A group of 49 patients initiated statin treatment later than 2 years after HT (median 3 years, range 2.4 to 5.2) [late statin (LS)]. These patients developed intolerance to statins early post-transplant or had other reasons, such as malnutrition with very low LDL levels or persistent transaminase elevation due to liver disease. Patients intolerant to statins reported myalgia or other muscular symptoms promptly after statin initiation; hence, statins were discontinued and reinitiated later after HT when the reasons for discontinuation had been resolved. Pravastatin was the preferred first-line statin in all patients due to lack of interaction with cytochrome P450 3A4 and minimal intrinsic muscle toxicity. The starting dose was 20 mg/day, and the maximum dose allowed was 80 mg/day. The dose was up-titrated as soon as possible to the highest allowable dose tolerated by the patient. The hydrophilic rosuvastatin (10–20 mg/day), the lipophilic atorvastatin (10–80 mg/day), or simvastatin (10–40 mg/day) were used if the LDL cholesterol was not decreased substantially by pravastatin.

Biopsies

Routine endomyocardial biopsies were performed according to our previously described institutional protocols.14–16 Each biopsy result was graded and assigned a grading for acute cellular or antibody-mediated rejection based on ISHLT grading. Total rejection and any rejection scores were calculated for each patient both at baseline (until the first IVUS examination) and during follow-up (from the time of first IVUS examination up to the time of last follow-up) in both ES and LS groups, based on the formulas previously described by our group.15,16 Briefly, total rejection score represents rejection severity and was calculated for each patient as the sum of the ISHLT rejection grades (0R was considered as 0, 1R as 1, 2R as 2, and 3R as 3) divided by the total number of biopsies, while any rejection score, which represents the extent of rejection, was calculated as the sum of positive biopsies (any ISHLT rejection grade of 1R or higher regardless of severity was given a score of 1) divided by the total number of biopsies performed for each individual patient. Moreover, we calculated the rates of patients who had events of moderate-to-severe (ISHLT rejection grades 2R or 3R) and rates of patients who had severe rejection (ISHLT rejection grade 3R) both at baseline and during follow-up among the two study groups.

Coronary angiography and intravascular ultrasound assessment

Coronary angiography with three-dimensional (3D) IVUS has been performed since 2004 on most cardiac transplant recipients at baseline 2 months after HT and subsequently on an annual basis as part of the surveillance for CAV or with any change in clinical status (in both groups). CAV was classified according to the ISHLT criteria. For assessment of CAV progression, 339 patients with two or more IVUS examinations were included for serial 3D IVUS volumetric analysis. The last IVUS was performed 4.9 ± 3.3 years after the first IVUS in the ES initiation group and 4.6 ± 3.4 years in the LS group.

Intravascular ultrasound was performed during routine CA after intracoronary administration of 100 to 200 µg nitroglycerin. The details of this method have been described previously.14–16 Proximal and mid left anterior descending coronary artery regions were defined for the interrogated artery. Starting with the first complete vascular ring distal to the bifurcation with the left circumflex artery lumen, plaque volume (PV), vessel volume (VV), and lumen volume (LV) were analysed. Each measured volume was normalized to the examined segment length (SL) (mm³/mm) to compensate for differences in examined vessel SL. The plaque index (PI) was calculated based on the formula: (PV/VV) × 100%. CAV progression was assessed by calculating the change in PV, VV, LV, and PI between the first and last follow-up IVUS examinations for each individual patient.

Outcomes

The primary outcomes of this study were as follows: (i) effects on levels of LDL, HDL, total cholesterol, and triglycerides during follow-up; (ii) progression of CAV by IVUS measurements during follow-up; (iii) all-cause mortality; (iv) CAV-related death, defined as death as a result of myocardial infarction confirmed by pathological examination and/or an increase in cardiac enzymes or sudden death in the setting of progressive CAV; (v) non-fatal CAV-related events including one of the following: allograft failure associated with known CAV in the absence of significant rejection or significant organic tricuspid valve regurgitation, myocardial infarction, or coronary angioplasty due to advanced CAV; (vi) all CAV-associated events; and (vii) composite of all-cause death and CAV-associated events. We calculated time to clinical events and CAV progression, from baseline IVUS to last clinical encounter or last IVUS examination, respectively. All patients who included at least one IVUS examination were included in the analysis of survival and time to CAV-related events. Survival and clinical events’ information were obtained from subsequent clinic visits and review of death certificates.

Statistical analysis

All variables were tested for normal data distribution. Normally distributed data were expressed as means ± standard deviation. Non-normally distributed data were presented as the median with the interquartile range. Patients’...
characteristics were compared between region using \( \chi^2 \) test for categorical variables, analysis of variance for normally distributed continuous variables, and Kruskal–Wallis test for continuous variables with skewed distribution. A Cox regression model, with adjustment for clinically significant factors (recipient age, gender, and ischaemic cardiomyopathy prior to transplant, time from transplant to baseline IVUS study, total rejection score, \( \Delta \) LDL between baseline and last follow-up, and conversion from CNI to SRL as primary immunosuppression), was fit to determine the factors associated with the main outcomes of our study. All significance tests were two tailed and conducted at the 5% significance level. Data were analysed with the JMP 8.0 (SAS Institute, Inc, Cary, NC) and SPSS 23 (SPSS Inc, Chicago, IL) software.

Results

Patient characteristics

The study cohort consisted of 409 HT recipients who underwent transplantation between 1994 and early 2015. We identified 339 patients who had two or more IVUS examinations and included for volumetric assessment and progression of CAV analysis. Table 1 provides baseline demographic and clinical characteristics on ES and LS groups of patients who had at least two IVUS examinations. Compared with patients in the ES group, those started late on statins were significantly younger by 7.3 ± 3.1 years, had younger donor age (\( P = 0.002 \)), longer time from HT to conversion to SRL (1.9 (0.7–5.9) vs. 1.1 (0.4–2.8); \( P = 0.02 \)), and longer time to baseline IVUS (2.1 (1.0, 6.4) vs. 1.2 (0.5, 3.2); \( P = 0.01 \)) years post-transplant. Other baseline variables, including ischaemic time, cytomegalovirus viremia, secondary immunosuppressants and use of steroids, total and any rejection scores, rates of 2R or 3R acute cellular rejection, and antiplatelet and antihypertensive treatment, were not different between groups. Sixty-one per cent of patients in the LS group and 71% in the ES group were converted from CNI-based to SRL-based immunosuppression. Our conversion protocol has been previously described.14–16 Laboratory parameters are presented in Table 1. Baseline glucose, creatinine, and eGFR were not different between groups. There were no significant differences in baseline lipid profile with the exception of lower HDL cholesterol in the LS group (57.1 ± 17.7 vs. 63.1 ± 19.2 mg/dL; \( P = 0.04 \)), baseline total or any rejection scores, baseline allograft left ventricular ejection fraction (%), and in baseline ISHLT CAV grades between the two groups.

At the end of follow-up, there were no differences in cellular rejection rates. Cellular rejection \( \geq 2R \) was found in 12.6% of patients in the ES group vs. 7.5% in the LS group (\( P = 0.24 \)). Severe 3R rejection was seen in 1.8% vs. 1.5% in ES vs. LS groups, respectively (\( P = 0.90 \)). No significant changes in allograft function between groups were identified (left ventricular ejection fraction 60.6% ± 9.0% vs. 60.3% ± 8.7% in ES vs. LS, respectively; \( P = 0.82 \)).

Plaque progression

Volumetric measurements of plaque progression by coronary 3D IVUS at baseline and at last follow-up IVUS available are presented in Table 2. The mean follow-up time from first to last IVUS examination was 4.6 ± 3.4 years in the LS and 4.9 ± 3.3 years in the ES group (\( P = 0.56 \)). At baseline, the left anterior descending artery PI (28.3% ± 11.6% vs. 24.6% ± 10.4% in ES vs. LS groups, respectively; \( P = 0.037 \)) and PV normalized to vessel length (PV/SL in mm³/mm) (4.4% ± 2.5% vs. 3.4% ± 2.1% mm³/mm in ES vs. LS groups, respectively; \( P = 0.013 \)) were significantly higher in the ES compared with the LS group. The VV normalized to vessel length (VV/SL in mm³/mm) and LV normalized to vessel length (LV/SL in mm³/mm) were not significantly different between groups (Table 2).

During follow-up, PI% was significantly increased in both groups, but the \( \Delta \) change between last follow-up IVUS and baseline measurement was significantly lower in the ES compared with the LS group (+3.8 ± 1.7 vs +8.2 ± 3.6; \( P = 0.0008 \)) (Figure 1). Similarly, PV/SL was significantly increased in both groups, but the \( \Delta \) change was significantly lower in the ES vs. the LS group (+0.8 ± 0.3 vs. +1.9 ± 1.2; \( P = 0.04 \)). The follow-up PI% and PV/SL were not significantly different between groups. The VV/SL was significantly increased at follow-up in both groups, but neither the last follow-up measurement nor the \( \Delta \) change was significantly different between groups (Table 2). Lastly, the LV/SL increased significantly in the ES group (11.4 ± 4 vs. 10.8 ± 3.8; \( P = 0.031 \)) only, with the differences in \( \Delta \) changes and last follow-up measurements being not significantly different.

A subgroup analysis of CAV progression was performed in CNI vs. SRL groups. Patients who were converted to SRL-based immunosuppression were included in the SRL group, whereas those who maintained on CNI-based immunosuppression were included in the CNI group. The mean follow-up time from the first to the last IVUS examination was 3.9 ± 3.1 years in the CNI group and 4.7 ± 3.3 years in the SRL group (\( P = 0.09 \)). In aggregate, 71.9% of patients in the ES group and 61.2% of patients in the LS group converted to SRL. As we have previously shown,17 both PI% and PV/SL were significantly higher in the CNI vs. the SRL group, regardless of the timing of statin initiation (\( P < 0.0001 \) using one-way analysis of variance followed by Tukey’s post hoc test). Our current analysis showed that there was a trend towards an increased \( \Delta \) PV in the LS vs. ES in patients maintained on CNI therapy (\( P = 0.06 \); \( n = 82 \) for ES and \( n = 19 \) for LS) and a trend towards an increased \( \Delta \) PI in the LS vs. ES in both CNI (\( P = 0.09 \)) and SRL (\( P = 0.07 \); \( n = 208 \) for ES and \( n = 30 \) for LS) subgroups (Figure 2).

ESC Heart Failure 2018; 5: 1118–1129
DOI: 10.1002/ehf2.12329
Effects of statins on lipid profile

Among lipid profile parameters, we found a non-significant decrease of LDL cholesterol in the ES (−11, range: −37, 17) from baseline, which did not differ from the Δ change on LS (−8, range: −43, 16; \( P = 0.95 \)). Total cholesterol did not decrease significantly in any of the groups (Δ change in ES −20 (−51, 11.75) vs. Δ change in LS −10 (−59, 9; \( P = 0.093 \)). A significant decrease in HDL cholesterol was identified in the ES compared with the LS group [−9 (−21, 3) vs. −3 (−12.5, 6); \( P = 0.031 \)]. Lastly, no significant differences were found between ES and LS groups in terms of triglycerides levels [Δ change in ES 11 (−75, 49.5) vs. Δ change in LS 0 (−35.8, 72), \( P = 0.057 \)].

### Table 1: Baseline characteristics of patients with two or more IVUS examinations who started statins <2 years (early statin group) or ≥2 years (late statin group) after heart transplantation

|                          | Early statin group (n = 290) | Late statin group (n = 49) | \( P \) value |
|--------------------------|------------------------------|---------------------------|---------------|
| Age, years               | 52.9 ± 12.5                  | 45.6 ± 15.6               | 0.0004        |
| Male, n (%)              | 205 (70.7)                   | 32 (65.3)                 | 0.45          |
| Time from HT to first IVUS, years | 1.2 (0.5, 3.2)             | 2.1 (1.0, 6.4)           | 0.01          |
| Time from HT to statins, years | 0.08 (0.04, 0.18)         | 3.0 (2.4, 5.2)           | <0.0001       |
| Number of IVUS per patient | 4.0 ± 2.2                   | 3.4 ± 1.9                 | 0.07          |
| Diagnosis, n (%)         | 4.9 ± 3.3                    | 4.6 ± 3.4                 | 0.55          |
| LDL cholesterol, mg/dL   | 84 (29.0)                    | 10 (20.4)                 | 0.20          |
| Total cholesterol, mg/dL | 26.2 ± 4.6                   | 26.3 ± 6.3                | 0.95          |
| Ischaemic time, min      | 171.5 ± 53.9                 | 163.4 ± 62.2              | 0.42          |
| Donor age, years         | 33.5 ± 14.5                  | 22.0 ± 7.4                | 0.002         |
| Hypertension, n (%)      | 107 (36.9)                   | 23 (46.9)                 | 0.19          |
| Diabetes, n (%)          | 67 (23.1)                    | 18 (36.7)                 | 0.05          |
| HDL cholesterol, mg/dL   | 52 (17.9)                    | 7 (14.3)                  | 0.52          |
| Baseline primary IS, n (%) | 1.1 (0.4, 2.8)             | 1.9 (0.7, 5.9)           | 0.02          |
| Cyclosporine             | 169 (58.3)                   | 24 (49.0)                 | 0.23          |
| Tacrolimus               | 121 (41.7)                   | 25 (51.0)                 |               |
| Conversion to SRL, n (%) | 208 (71.7)                   | 30 (61.2)                 | 0.15          |
| Time from HT to IVUS, years | 4.0 ± 2.2                   | 3.4 ± 1.9                 | 0.07          |
| Time from HT to conversion to SRL, years | 1.1 (0.4, 2.8)            | 1.9 (0.7, 5.9)           | 0.02          |
| AZA/MMF, n (%)           | 84 (29.0)                    | 17 (34.7)                 | 0.42          |
| Glucose, mg/dL           | 206 (71.0)                   | 32 (65.3)                 |               |
| Steroids, n (%)          | 278 (95.9)                   | 47 (95.9)                 | 0.99          |
| Fibrates, n (%)          | 19 (6.6)                     | 5 (10.4)                  | 0.36          |
| Aspirin, n (%)           | 41 (14.1)                    | 6 (12.2)                  | 0.49          |
| Anti-coagulation, n (%)  | 53 (18.3)                    | 6 (12.2)                  | 0.51          |
| Diuretics, n (%)         | 206 (71.0)                   | 33 (67.4)                 | 0.60          |
| CCB, n (%)               | 172 (59.3)                   | 22 (44.9)                 | 0.16          |
| BB, n (%)                | 48 (16.6)                    | 11 (22.5)                 | 0.33          |
| ACE-I, n (%)             | 99 (34.1)                    | 18 (36.7)                 | 0.73          |
| Creatinine, mg/dL        | 209.8 ± 50.6                 | 201.8 ± 60.2              | 0.32          |
| Creatinine, mg/dL        | 111.6 ± 31.0                 | 114.4 ± 37.9              | 0.58          |
| eGFR, mL/min/1.73 m²     | 1.4 ± 0.5                    | 1.5 ± 0.5                 | 0.64          |
| eGFR, mL/min/1.73 m²     | 42.8 ± 28.6                  | 46.4 ± 47.1               | 0.75          |
| Triglycerides, mg/dL     | 62.8 ± 28.6                  | 64.4 ± 47.1               | 0.75          |
| Triglycerides, mg/dL     | 144 (105, 209)               | 153 (109.5, 220)          | 0.59          |
| HDL cholesterol, mg/dL   | 63.1 ± 19.2                  | 57.1 ± 17.7               | 0.04          |
| LDL cholesterol, mg/dL   | 111.7 ± 40.4                 | 110.2 ± 42.5              | 0.81          |
| Graft LVEF, %            | 112.7 ± 7.4                  | 63.7 ± 5.5                | 0.20          |
| Total rejection score    | 0.30 (0.16, 0.50)            | 0.25 (0.0, 0.43)          | 0.06          |
| Any rejection score      | 0.28 (0.13, 0.45)            | 0.24 (0.0, 0.38)          | 0.06          |
| Patients with ≥2R rejection, n (%) | 75 (25.9)            | 13 (26.5)                 | 0.80          |
| Patients with 3R rejection, n (%) | 22 (7.6)            | 4 (8.2)                   | 0.84          |

ACE-I, angiotensin-converting enzyme inhibitor; AZA, azathioprine; BB, beta-blocker; BMI, body mass index; CAV, cardiac allograft vasculopathy; CCB, calcium channel blocker; CMV, cytomegalovirus; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; HT, heart transplantation; ICM, ischaemic cardiomyopathy; IS, immunosuppression; ISHLT, International Society for Heart and Lung Transplantation; IVUS, intravascular ultrasound; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction; MMF, mycophenolate mofetil; SRL, sirolimus.

Data expressed as mean (±standard deviation), median (interquartile range), or \( n \) (%).
Effects of statins on clinical outcomes

We analysed 347 patients in the ES and 67 patients in the LS group with median follow-up of 8.2 and 7.3 years, respectively (range: 2.7–8.2 years). Baseline characteristics of the entire cohort comparing ES and LS groups are shown in Table 3. At baseline, patients in the ES group were significantly older, with younger donor age, higher rates of conversion to SRL, and significantly higher total cholesterol and HDL cholesterol levels. ES initiation was associated with significantly lower all-cause mortality on unadjusted Cox proportional hazards modelling (hazard ratio [HR] 0.57 [95% confidence interval (CI) 0.37–0.92]; \( P = 0.022 \)) (Table 4 and Figure 3A). After adjusting for recipient age, gender, and ischaemic cardiomyopathy prior to transplant, time from transplant to baseline IVUS study, total rejection score, \( \Delta \) LDL cholesterol, and conversion from CNI to SRL as primary immunosuppression, the risk of mortality was non-significantly decreased in the ES group (HR 0.64 (95% CI 0.41–1.05); \( P = 0.077 \)) (Table 4). CAV-associated death was also significantly decreased in the ES group in the unadjusted model (HR 0.36 (95% CI 0.17–0.79); \( P = 0.013 \)), but in the multivariate Cox proportional hazards model, the CAV-related death risk was non-significantly decreased (HR 0.53 (95% CI 0.25–1.21); \( P = 0.128 \)) (Table 4). Although the non-fatal CAV events were less frequent in the ES group, the association between the timing of statin initiation and outcome did not reach statistical significance. When we combined and analysed CAV-related death and non-fatal CAV-related outcomes in a composite outcome, we found significantly lower both unadjusted (HR 0.38 (95% CI 0.22–0.71); \( P = 0.003 \)) and adjusted (HR 0.48 (95% CI 0.27–0.91); \( P = 0.025 \)) risks of CAV-related events (Table 4 and Figure 3B). In a similar fashion, the composite endpoint of all-cause death and CAV-related events

---

### Table 2 Differences in plaque volumetric measurements and allograft vasculopathy progression between early and late statin groups as assessed by IVUS during follow-up

|                      | Early statin group (n = 290) | Late statin group (n = 49) | \( P \) value |
|----------------------|-----------------------------|---------------------------|-------------|
| Time from first to last IVUS, y | 4.9 ± 3.3                   | 4.6 ± 3.4                 | 0.55        |
| PV/SL, mm\(^3\)/mm | 4.4 ± 2.5                   | 3.4 ± 2.1                 | 0.013\(^b\) |
| Follow-up           | 5.2 ± 2.8                   | 5.3 ± 3.3                 | 0.572\(^b\) |
| \( P \) value       | <0.0001\(^a\)              | 0.0001\(^a\)              | 0.040\(^c\) |
| VV/SL, mm\(^3\)/mm | Baseline 15.2 ± 5.0         | 13.8 ± 5.0                | 0.071\(^b\) |
| Follow-up           | 16.6 ± 4.9                  | 15.5 ± 5.2                | 0.063\(^b\) |
| \( P \) value       | <0.0001\(^a\)              | 0.046\(^a\)               | 0.283\(^c\) |
| LV/SL, mm\(^3\)/mm | Baseline 10.8 ± 3.8         | 10.4 ± 4.0                | 0.43\(^b\)  |
| Follow-up           | 11.4 ± 4.0                  | 10.2 ± 3.6                | 0.053\(^b\) |
| \( P \) value       | 0.031\(^a\)                | 0.62\(^a\)                | 0.068\(^c\) |
| Plaque index, %     | Baseline 28.3 ± 11.6        | 24.6 ± 10.4               | 0.037\(^b\) |
| Follow-up           | 32.1 ± 13.3                 | 32.8 ± 14.0               | 0.760\(^b\) |
| \( P \) value       | <0.001\(^a\)               | 0.044\(^a\)               | 0.008\(^c\) |

LV, lumen volume; PI, plaque index; PV, plaque volume; SL, segment length; VV, vessel volume. \( \Pi = (\text{PV/VV}) \times 100\% \).

Data expressed as mean (±standard deviation).

*Paired \( t \)-test.

\(^b\) \( t \)-test.

\(^c\) Analysis of covariance test with baseline value as a covariable.

---

**Effects of statins on clinical outcomes**

We analysed 347 patients in the ES and 67 patients in the LS group with median follow-up of 8.2 and 7.3 years, respectively (range: 2.7–8.2 years). Baseline characteristics of the entire cohort comparing ES and LS groups are shown in Table 3. At baseline, patients in the ES group were significantly older, with younger donor age, higher rates of conversion to SRL, and significantly higher total cholesterol and HDL cholesterol levels. ES initiation was associated with significantly lower all-cause mortality on unadjusted Cox proportional hazards modelling (hazard ratio [HR] 0.57 [95% confidence interval (CI) 0.37–0.92]; \( P = 0.022 \)) (Table 4 and Figure 3A). After adjusting for recipient age, gender, and ischaemic cardiomyopathy prior to transplant, time from transplant to baseline IVUS study, total rejection score, \( \Delta \) LDL cholesterol, and conversion from CNI to SRL as primary immunosuppression, the risk of mortality was non-significantly decreased in the ES group (HR 0.64 (95% CI 0.41–1.05); \( P = 0.077 \)) (Table 4). CAV-associated death was also significantly decreased in the ES group in the unadjusted model (HR 0.36 (95% CI 0.17–0.79); \( P = 0.013 \)), but in the multivariate Cox proportional hazards model, the CAV-related death risk was non-significantly decreased (HR 0.53 (95% CI 0.25–1.21); \( P = 0.128 \)) (Table 4). Although the non-fatal CAV events were less frequent in the ES group, the association between the timing of statin initiation and outcome did not reach statistical significance. When we combined and analysed CAV-related death and non-fatal CAV-related outcomes in a composite outcome, we found significantly lower both unadjusted (HR 0.38 (95% CI 0.22–0.71); \( P = 0.003 \)) and adjusted (HR 0.48 (95% CI 0.27–0.91); \( P = 0.025 \)) risks of CAV-related events (Table 4 and Figure 3B). In a similar fashion, the composite endpoint of all-cause death and CAV-related events
was significantly decreased in the ES group in both unadjusted [HR 0.54 (95% CI 0.36–0.84); P = 0.007] and adjusted models [HR 0.58 (95% CI 0.38–0.912); P = 0.019] (Table 4 and Figure 3C).

**Discussion**

Our study was designed to investigate effects of statin treatment on long-term progression of CAV using serial coronary 3D IVUS and clinical outcomes between early and late initiation of therapy in a large and contemporary HT cohort. The main findings can be summarized as follows: (i) in a cohort of 339 patients who had at least two IVUS studies, early initiation of statins was associated with attenuated progression of CAV; (ii) in a total cohort of 409 patients who underwent HT, ES therapy was associated with significantly lower CAV-associated non-fatal and fatal events as well as the composite of all-cause mortality and CAV-related events, after adjustment for clinical parameters; and (iii) CAV progression was attenuated with ES initiation, independently of SRL-based or CNI-based immunosuppression.

In non-transplant patients with or at risk for cardiovascular disease, the benefits of statin therapy are well established.\(^1\)\(^8\) In HT recipients, dyslipidemia (elevation in total cholesterol, LDL cholesterol, and triglycerides) occurs in up to 83% during immunosuppressive therapy.\(^1\)\(^9\),\(^2\)\(^0\) De novo dyslipidemia develops within the first 3 months after HT, with corticosteroids, tacrolimus/SRL, renal insufficiency, and diabetes mellitus being the major contributing factors.\(^2\)\(^1\) Treatment of dyslipidemia after HT is well established for prevention of progression of allograft vasculopathy.

Data from randomized controlled studies suggest improved clinical outcomes on statin therapy after HT. In part, the derived benefit is likely due to pleiotropic effects beyond lipid lowering, such as inhibition of inflammatory activity and cytokine activation, attenuation of endothelial dysfunction, and attenuation of vascular hypercoagulability.\(^2\)\(^2\) In the first prospective, randomized open-label study of 97 HT recipients, pravastatin at a starting dose of 20 mg/day within 2 weeks after transplantation and up-titration to 40 mg/day at 1 month resulted in significant reduction of LDL cholesterol (by 41 mg/dL compared with controls), lower CAV incidence as determined by angiography or autopsy, lower maximal intimal thickness on IVUS, and a significant increase in patient survival by ~16%.* These benefits persisted at 10 years, despite a 42% patient crossover to pravastatin in the second year and 81% by the 10th year. However, the intention-to-treat analysis indicated improved survival after HT in the early initiation pravastatin group compared with controls despite 100% late crossover of the controls to simvastatin by 4 years.\(^1\)\(^3\),\(^1\)\(^1\) A concern with statin therapy is development of myopathy due to interaction with CYP3A4.
inhibitors such as cyclosporine, tacrolimus, and SRL. Pravastatin is not metabolized extensively by CYP3A4; hence, it is better tolerated. The safety and efficacy of different statins was assessed in a prospective, open-label study of 24 patients assigned to pravastatin 20 mg, 26 patients assigned to simvastatin 10 mg, within 4 weeks after HT, and 37 controls.23 Both statins were well tolerated without any cases of muscle injury and had similar survival rates, which were significantly higher than controls. LDL cholesterol reduction was ~12% more pronounced with simvastatin. A more recent meta-analysis of four randomized controlled trials and six observational studies reported significant reduction in all-cause mortality, hemodynamically significant/fatal rejection, incidence of coronary vasculopathy, and terminal cancer with various

Table 3  Baseline characteristics of early vs. late statin groups including all patients transplanted until January 2015 with at least one IVUS study for clinical outcome analysis

|                        | Early statin group (n = 342) | Late statin group (n = 67) | P value |
|------------------------|-----------------------------|---------------------------|---------|
| Age, years             | 52.8 ± 12.9                 | 46.3 ± 17.5               | 0.0004  |
| Male, n (%)            | 238 (69.6)                  | 46 (68.7)                 | 0.88    |
| Time from HT to first IVUS, years | 1.2 (0.5, 3.5)        | 2.1 (1.1, 6.6)            | 0.01    |
| Time from HT to statins, years | 0.08 (0.03, 0.18)    | 3.0 (2.5, 5.5)            | <0.0001 |
| Duration of follow-up from first IVUS, years | 6.0 (3.5, 9.5)     | 4.2 (2.6, 10.2)           | 0.03    |
| Duration of follow-up from HT, years | 8.2 (7.7, 8.2)      | 5.3 (4.5, 13.3)           | 0.78    |
| Aetiology of heart failure, n (%) | IC 100 (29.2)              | 15 (22.4)                 | 0.25    |
|                        | BMI, kg/m²                   | 26.1 ± 4.8                | 25.9 ± 5.7 | 0.70 |
|                        | Ischaemic time, min         | 169.9 ± 54.7              | 165.9 ± 58.6 | 0.64 |
|                        | Donor age, years            | 33.0 ± 14.3               | 23.7 ± 9.9 | 0.005 |
|                        | Hypertension, n (%)         | 127 (37.1)                | 31 (46.3)  | 0.16    |
|                        | Diabtes, n (%)              | 79 (23.1)                 | 21 (31.3)  | 0.16    |
|                        | Baseline primary IS, n (%)  | 100 (95.4)                | 10 (7.6)   | 0.16    |
|                        | Cyclosporine                | 195 (57.0)                | 32 (47.8)  | 0.70    |
|                        | Tacrolimus                  | 147 (43.0)                | 35 (52.2)  | 0.70    |
|                        | Conversion to SRL, n (%)    | 236 (69.0)                | 36 (53.7)  | 0.02    |
|                        | Time from HT to conversion to SRL, years | 1.1 (0.4, 3.2)      | 2.0 (0.7, 6.2) | 0.01 |
|                        | AZA/MMF, n (%)              | 97 (28.4)                 | 22 (32.8)  | 0.47    |
|                        | MMF                         | 245 (71.6)                | 45 (67.2)  | 0.78    |
|                        | Steroids, n (%)             | 329 (96.2)                | 63 (94.0)  | 0.78    |
|                        | Fibrates, n (%)             | 20 (5.9)                  | 5 (7.6)    | 0.60    |
|                        | Aspin, n (%)                | 49 (14.3)                 | 8 (11.9)   | 0.84    |
|                        | Plavix, n (%)               | 9 (2.6)                   | 3 (4.5)    | 0.44    |
|                        | Anti-coagulation, n (%)      | 59 (17.3)                 | 9 (13.4)   | 0.64    |
|                        | Diuretics, n (%)            | 235 (62.7)                | 43 (64.2)  | 0.47    |
|                        | CCB, n (%)                  | 196 (57.3)                | 32 (47.9)  | 0.31    |
|                        | BB, n (%)                   | 53 (15.5)                 | 19 (28.4)  | 0.02    |
|                        | ACE-I, n (%)                | 113 (33.0)                | 23 (34.3)  | 0.84    |
|                        | Glucose, mg/dL              | 111.6 ± 31.5              | 111.6 ± 34.1 | 0.98 |
|                        | Creatinine, mg/dL           | 1.4 ± 0.5                 | 1.43 ± 0.53 | 0.93 |
|                        | eGFR, mL/min/1.73 m²        | 62.2 ± 28.4               | 67.5 ± 46.0 | 0.22 |
|                        | Uric acid, mg/dL            | 6.3 ± 1.9                 | 6.6 ± 2.2  | 0.18    |
|                        | Total cholesterol, mg/dL    | 208.7 ± 52.3              | 190.4 ± 56.9 | 0.01 |
|                        | Triglycerides, mg/dL        | 144 (105, 211)            | 146.5 (103.8, 199.5) | 0.88 |
|                        | HDL cholesterol, mg/dL      | 62.4 ± 19.2               | 55.3 ± 17.1 | 0.007 |
|                        | LDL cholesterol, mg/dL      | 110.5 ± 39.7              | 101.2 ± 41.0 | 0.09 |
|                        | Graft LVEF, %               | 62.4 ± 7.2                | 63.4 ± 5.7  | 0.26    |
|                        | Total rejection score       | 0.33 (0.17, 0.50)         | 0.25 (0.0, 0.43) | 0.013 |
|                        | Any rejection score         | 0.30 (0.15, 0.47)         | 0.24 (0.0, 0.39) | 0.013 |
|                        | Patients with ≥2R rejection, n (%) | 92 (26.9)               | 16 (23.9)  | 0.70    |
|                        | Patients with 3R rejection, n (%) | 29 (8.5)                | 6 (9.0)    | 0.88    |
|                        | ISHLT CAV grade at baseline | Grade 0 215 (62.9)        | 45 (67.1)  | 0.18    |
|                        |                              | Grade 1 117 (34.2)        | 18 (26.9)  | 0.78    |
|                        |                              | Grade 2 1 (0.3)           | 2 (3.0)    | 0.88    |
|                        |                              | Grade 3 9 (2.6)           | 2 (3.0)    | 0.88    |

ACE-I, angiotensin-converting enzyme inhibitor; AZA, azathioprine; BB, beta-blocker; BMI, body mass index; CAV, cardiac allograft vasculopathy; CCB, calcium channel blocker; CMV, cytomegalovirus; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; HT, heart transplantation; ICM, ischaemic cardiomyopathy; IS, immunosuppression; ISHLT, International Society for Heart and Lung Transplantation; IVUS, intravascular ultrasound; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction; MMF, mycophenolate mofetil; SRL, sirolimus.

Data expressed as mean (±standard deviation), median (interquartile range), or n (%).
Table 4. Cox regression analysis of clinical outcomes presented as hazard ratios (95% CI) for early vs. late statin initiation following heart transplantation.

| Outcome | HR for early vs. late statin therapy | 95% CI | P value |
|---------|--------------------------------------|--------|---------|
| All-cause death | Unadjusted | 0.57 | 0.37–0.92 | 0.022 |
| CAV-associated death | Unadjusted | 0.36 | 0.17–0.79 | 0.013 |
| Non-fatal CAV events | Unadjusted | 0.42 | 0.19–1.01 | 0.053 |
| Fatal and non-fatal CAV events | Unadjusted | 0.38 | 0.22–0.71 | 0.003 |
| Composite of all-cause death and all CAV events | Unadjusted | 0.54 | 0.36–0.84 | 0.007 |

HR, hazard ratio; CI, confidence interval; CAV, cardiac allograft vasculopathy.

*Adjusted for recipient age, gender, and ischaemic cardiomyopathy prior to transplant, time from transplant to baseline IVUS study, total rejection score, Δ LDL between baseline and last follow-up, and conversion from calcineurin inhibitor to sirolimus as primary immunosuppression.

Based on the aforementioned evidence, the ISHLT guidelines strongly recommend (Class I; Level of Evidence A) initiation of statins early after HT, irrespective of lipid profile.

In our study, statin treatment resulted in approximately −10% and −8.2% reduction from baseline in LDL cholesterol in ES and LS groups, respectively. At the end of follow-up, the IVUS parameters PI%, PV/SL, VV/SL, and LV/SL were not significantly different between groups. Despite similar burden of CAV based on the last IVUS assessment, the progression of CAV was attenuated in the ES group as these patients had significantly higher burden of disease at baseline IVUS. Furthermore, the effects of ES treatment on CAV-related events remain significant after adjustment after changes in LDL cholesterol. Our data suggest both lipid-lowering dependent and independent effects of statins in HT recipients. The anti-proliferative and immune-modulating effects of statin can be explained by decreased synthesis of mevalonate, farnesyl pyrophosphate, and geranyl pyrophosphate, which mediate intracellular signal transduction and lead to diminished smooth muscle cell proliferation and suppression of natural killer cell activity. Although previous studies have suggested beneficial effects of statins on the incidence of rejection, we did not confirm these findings in our cohort. Thus, the differences in all-cause mortality can be explained in part by lower CAV-related events in the ES group. Finally, the effects of statins on CAV progression were similar in subgroups with SRL-based and CNI-based immunosuppression, and the benefit on CAV-related events remained after adjustment for conversion to SRL. As we have previously shown, SRL-based regimens attenuate CAV progression in comparison with CNI-based regimens, and ES initiation seems to exert an incremental benefit to SRL-based regimens.

Our study included a group of patients that started statin therapy later after HT. Most of these HT recipients had experienced possible statin-related adverse effects such as myalgia, hepatotoxicity, high creatinine kinase without muscle symptoms, or rarely, rhabdomyolysis. Although the safety and efficacy of statins is well established, previous reports have suggested that 10–20% of HT recipients may experience statin-related adverse effects. Cyclosporine has been found to increase blood levels not only of statins metabolized through cytochrome 3A4 but also of pravastatin, which is not metabolized through cytochrome, by inhibition of multidrug resistant protein 2. Moreover, myopathy may become more frequent after conversion to SRL-based immunosuppression. Other reported risk factors for statin intolerance include advanced age, frailty, chronic kidney disease, and recent major surgery, and certainly, these factors are encountered more frequently among HT recipients. Therefore, it is possible that the late initiation of statin group consists of patients with higher burden of co-morbidities and more severe and prolonged heart failure course before HT, which can lead to cachexia, sarcopenia, malnutrition, and poor tolerance to statins. These considerable differences in disease nature between the ES and LS patients may make routine matching and comparison between the two groups more challenging.

**Study limitations**

This study is subject to limitations inherent to any study with observational, retrospective design and the non-randomized treatment assignment. Furthermore, patients with rapidly progressive CAV without serial IVUS exams were excluded from the analysis, and the results may not be applicable to this group. The performance of IVUS analysis in the left anterior descending artery may also lead to underestimation of disease burden. Finally, we acknowledge that LS patients may differ significantly in disease nature from the ES group, which may limit the ability of routine matching to make the desirable comparisons.

Despite these limitations, our study has several strengths and adds to current knowledge. First, all patients were evaluated with serial 3D IVUS exams on an annual basis as part of...
the surveillance for CAV or with any change in clinical status, unlike some of the previous studies that used CA or post-mortem findings. The sensitivity of coronary angiogram is limited by the diffuse nature of CAV. Although the use of two-dimensional IVUS improves sensitivity, it is limited by difficulty with spatial registration and inability to assess the full extent of vascular disease. Imaging with 3D IVUS allows rapid and accurate measurement of arterial length, volume, and
plaque dimensions in addition to luminal area and can demonstrate the full extent of CAV. Length and volume measurements show excellent correlation with in vitro histomorphometry measurements and in vivo angiography. Second, we routinely utilize SRL-based immunosuppression with early conversion from tacrolimus-based regimens in most patients, to prevent or delay the progression of CAV. Our study supports an incremental benefit of statins over the use of SRL for mitigating CAV events. Finally, the long duration of follow-up and the sample size provide important information about the effects of statins on CAV progression and outcomes.

Conclusions

In a single-centre cohort, early initiation of statins is associated with attenuated CAV progression and improves CAV-related outcomes. Thus, the present study reinforces the findings from previous studies on the importance of ES initiation following HT. Further studies may be helpful to investigate the effects of different statin types and doses on lipoprotein particle density/size and function combined with high-resolution evaluation of the coronary artery wall structure and composition.

References

1. Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb S, Levvey BJ, Meiser B, Rossano JW, Yusen RD, Strehlik J. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report—2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 2015; 34: 1244–1254.
2. Nagji AS, Hranjec T, Swenson BR, Kern JA, Bergin JD, Jones DR, Kron IL, Lau CL, Alawadi G. Donor age is associated with chronic allograft vasculopathy after adult heart transplantation: implications for donor allocation. Ann Thorac Surg 2010; 90: 160–175.
3. Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res 2006; 99: 801–815.
4. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK 3rd, Bohemier JP, Brozova SC, Dec GW, Ventura HO, Kirkin JK, Bourge RC, Miller LW. Heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database J Heart Lung Transplant 1998; 17: 744–753.
5. Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, Madsen J, Parameshwar J, Starling RC, Uber PA. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy. J Heart Lung Transplant 2010; 29: 717–727.
6. Tuzcu EM, Kapadia SR, Sachar R, Ziad KM, Crowe TD, Feng J, Magyar WA, Hobbs RE, Starling RC, Young JB, McCarthy P, Nissen SE. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005; 45: 1538–1542.
7. Weis M, Pehlivani S, Meiser BM, von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001; 38: 814–818.
8. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlborg K, Linz W, Itter G, Rosen R, Böhml M, Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450–1457.
9. Kobashigawa JA, Katzenelson S, Laks H, Johnson JA, Yeatman I, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621–627.
10. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, Seidel D, Reichart B. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96: 1398–1402.
11. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Krobot K, Steinbeck G, Seidel D, Reichart B. Simvastatin initiates early after heart transplantation: 8-year prospective experience. Circulation 2003; 107: 93–97.
12. Bilschick KC, Henrikson CA, Skojec D, Kasper EK, Blumenthal RS. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 2004; 148: 200–210.
13. Kobashigawa JA, Moriguchi JD, Laks H, Wener L, Hage A, Hamilton MA, Cogert G, Marquez A, Vassilakis ME, Patel J, Yeatman L. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005; 24: 1736–1740.

14. Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005; 24: 2129–2136.

15. Raichlin E, Bae JH, Khalpey Z, Edwards BS, Kremers WK, Clavell AL, Rodeheffer RJ, Frantz RP, Riñah C, Lerman A, Kushwaha SS. Conversion to sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation 2007; 116: 2726–2733.

16. Topilsky Y,Hasin T, Raichlin E, Boilson BA, Schirger JA, Pereira NI, Edwards BS, Clavell AL, Rodeheffer RJ, Frantz RP, Maleis S, Park SJ, Daly RC, Lerman A, Kushwaha SS. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation 2012; 125: 708–720.

17. Asher R, Brissouls A, Kremers WK, Adigun R, Boilson BA, Pereira NI, Edwards BS, Clavell AL, Schirger JA, Rodeheffer RJ, Frantz RP, Joyce LD, Maleis S, Stulak JM, Daly RC, Tilford J, Choi WG, Lerman A, Kushwaha SS. Long-term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients. J Am Coll Cardiol 2018; 71: 636–650.

18. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell I, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581–590.

19. Rudas L, Pflugfelder PW, McKenzie FN, Meniks AH, Novick RJ, Kostuk WJ. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol 1990; 66: 1135–1143.

20. Ballantyne CM, Radovanovic B, Farmer JA, Frazier OH, Chandler L, Payton-Ross C, Cooanougher B, Jones PH, Young JB, Goto AM Jr. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992; 19: 1315–1320.

21. Lake KD, Reutzel T, Pritzer MR, Jorgensen CR, Emery RW. The impact of steroid withdrawal on the development of lipid abnormalities and obesity in heart transplant recipients. J Heart Lung Transplant 1993; 12: 580–590.

22. Holschermann H, Hilgendorff A, Kemkes-Matthes B, Schönbürg M, Bauer EP, Tillmanns H, Haberbusch W. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation 2000; 69: 1830–1836.

23. Mehran MR, Uber PA, Vivekananthan K, Solis S, Scott RL, Park MH, Milani RV, Lavi CJ. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. JAMA 2002; 40: 1609–1614.

24. Vallakati A, Reddy S, Dunlap ME, Taylor DO. Impact of statin use after heart transplantation. A meta-analysis. Circ Heart Fail 2016; 9: e003265.

25. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martineilli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kloury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbs F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolff G, Delgado D, Eisen H, Goldberg L, Hosenpud J, Johnson M, Kehag A, Lewis C, O’Connell J, Rogers J, Ross H, Russell S, Vanheecke J. International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914–956.

26. Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 1996; 34: 51–61.

27. Alfon J, Guasch JF, Berroze M, Badimon L. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Atherosclerosis 1999; 145: 325–331.

28. Marzor-Rivas R, Crespo-Leiro MG, Paniagua-Marin MJ, Linares-Garcia D, Muñiz-Garcia J, Aldama-López G, Piñón-Esteban P, Campo-Pérez R, Castro-Beiras A. Safety of statins when response is carefully monitored: a study of 336 heart recipients. Transplant Proc 2005; 37: 4071–4073.

29. Olbricht C, Wanner C, Eisenhauer T. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311–321.

30. Yamazaki M, Akiyama S, Niihuma K. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos 1997; 25: 1123–1129.

31. Alibadi AZ, Mahr S, Dunker D, Grömmmer M, Zimpfer D, Wolner E, Grimm M, Zuckermann AO. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation 2008; 86: 1771–1776.

32. Bae JH, Riñah CS, Edwards BS, Kushwaha SS, Mathew V, Prasad A, Holmes DR Jr, Lerman A. Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. Transplantation 2006; 82: 1108–1111.

33. White JA, Pflugfelder PW, Boughner DR, Kostuk WJ. Validation of a three-dimensional intravascular ultrasound imaging technique to assess atherosclerotic burden: potential for improved assessment of cardiac allograft coronary artery disease. Can J Cardiol 2003; 19: 1147–1153.